This result was consistent with published analyses of two randomized trials enrolling patients with stage II/III CRC treated with adjuvant chemotherapy, which concluded that the presence of KRAS mutational status did not show significant effects on survival or disease recurrence [45,46]. The gene discussed is KRAS; the disease is colorectal carcinoma.